Human immunodeficiency virus-associated plasmablastic lymphoma: Poor prognosis in the era of highly active antiretroviral therapy

Cancer

Volumn 118, Issue 21, 2012, Pages 5270-5277

  Castillo, Jorge J ^a   Furman, Michael ^a   Beltrán, Brady E ^b   Bibas, Michele ^c   Bower, Mark ^d   Chen, Weina ^e   Díez Martín, José L ^f   Liu, Jane J ^g   Miranda, Roberto N ^h   Montoto, Silvia ⁱ   Nanaji, Nahid M ^j   Navarro, José Tomás ^k   Seegmiller, Adam C ^l   Vose, Julie M ^m  

^a BROWN UNIVERSITY   (United States)

^b HOSPITAL NACIONAL EDGARDO REBAGLIATI MARTINS   (Peru)

^c NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^d CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^e QUEST DIAGNOSTICS NICHOLS INSTITUTE   (United States)

^f HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^g H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^h UNIVERSITY OF TEXAS   (United States)

ⁱ QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^j UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

^k HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^l VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^m UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

more..

Author keywords

acquired immunodeficiency syndrome; chemotherapy; highly active antiretroviral therapy; human immunodeficiency virus; plasmablastic

Indexed keywords

BORTEZOMIB; CD20 ANTIGEN; CD4 ANTIGEN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; MESNA; METHOTREXATE; PREDNISONE; THALIDOMIDE; VINCRISTINE;

ADULT; ADVANCED CANCER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CELL COUNT; CELL DIFFERENTIATION; CELL STRUCTURE; CLINICAL ARTICLE; DISEASE ASSOCIATION; DRUG RESPONSE; FEMALE; GENE REARRANGEMENT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MOUTH DISEASE; MYELOID LEUKEMIA; ONCOGENE MYC; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PLASMA CELL; PLASMABLASTIC LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SEQUENCE HOMOLOGY;

ADULT; AGED; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; HIV INFECTIONS; HUMANS; LYMPHOMA, AIDS-RELATED; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; PROGNOSIS; YOUNG ADULT;

EID: 84867848949     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27551     Document Type: Article

References (28)

1. Delecluse HJ, Anagnostopoulos I, Dallenbach F, et al. Plasmablastic lymphomas of the oral cavity: a new entity associated with the human immunodeficiency virus infection. Blood. 1997; 89: 1413-1420.
2. Stein H, Harris N, Campo E,. Plasmablastic lymphoma. In:, Swerdlow S, Campo E, Harris N, et al, eds. WHO Classification of Tumours of the Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: IARC; 2008: 256-257.
3. Castillo JJ, Reagan JL,. Plasmablastic lymphoma: a systematic review. ScientificWorldJournal. 2011; 11: 687-696.
4. Vega F, Chang CC, Medeiros LJ, et al. Plasmablastic lymphomas and plasmablastic plasma cell myelomas have nearly identical immunophenotypic profiles. Mod Pathol. 2005; 18: 806-815.
5. Chang CC, Zhou X, Taylor JJ, et al. Genomic profiling of plasmablastic lymphoma using array comparative genomic hybridization (aCGH): revealing significant overlapping genomic lesions with diffuse large B-cell lymphoma [serial online]. J Hematol Oncol. 2009; 2: 47.
6. Colomo L, Loong F, Rives S, et al. Diffuse large B-cell lymphomas with plasmablastic differentiation represent a heterogeneous group of disease entities. Am J Surg Pathol. 2004; 28: 736-747.
7. Teruya-Feldstein J, Chiao E, Filippa DA, et al. CD20-negative large-cell lymphoma with plasmablastic features: a clinically heterogenous spectrum in both HIV-positive and -negative patients. Ann Oncol. 2004; 15: 1673-1679.
8. Bogusz AM, Seegmiller AC, Garcia R, et al. Plasmablastic lymphomas with MYC/IgH rearrangement: report of 3 cases and review of the literature. Am J Clin Pathol. 2009; 132: 597-605.
9. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007; 25: 579-586.
10. Castillo JJ, Winer ES, Stachurski D, et al. Clinical and pathological differences between human immunodeficiency virus-positive and human immunodeficiency virus-negative patients with plasmablastic lymphoma. Leuk Lymphoma. 2010; 51: 2047-2053.
11. Castillo J, Pantanowitz L, Dezube BJ,. HIV-associated plasmablastic lymphoma: lessons learned from 112 published cases. Am J Hematol. 2008; 83: 804-809.
12. Biggar RJ, Chaturvedi AK, Goedert JJ, et al. AIDS-related cancer and severity of immunosuppression in persons with AIDS. J Natl Cancer Inst. 2007; 99: 962-972.
13. Valera A, Balague O, Colomo L, et al. IG/MYC rearrangements are the main cytogenetic alteration in plasmablastic lymphomas. Am J Surg Pathol. 2010; 34: 1686-1694.
14. Barrans S, Crouch S, Smith A, et al. Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. J Clin Oncol. 2010; 28: 3360-3365.
15. Li S, Lin P, Fayad LE, et al. B-cell lymphomas with MYC/8q24 rearrangements and IGH@BCL2/t(14;18)(q32;q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome. Mod Pathol. 2011; 25: 145-156.
16. Castillo JJ, Winer ES, Stachurski D, et al. HIV-negative plasmablastic lymphoma: not in the mouth. Clin Lymphoma Myeloma Leuk. 2011; 11: 185-189.
17. Castillo JJ, Morales D, Quinones P, et al. Lymphopenia as a prognostic factor in patients with peripheral T-cell lymphoma, unspecified. Leuk Lymphoma. 2010; 51: 1822-1828.
18. Ray-Coquard I, Cropet C, Van Glabbeke M, et al. Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas. Cancer Res. 2009; 69: 5383-5391.
19. Talaulikar D, Choudhury A, Shadbolt B, et al. Lymphocytopenia as a prognostic marker for diffuse large B cell lymphomas. Leuk Lymphoma. 2008; 49: 959-964.
20. Armstrong R, Bradrick J, Liu YC,. Spontaneous regression of an HIV-associated plasmablastic lymphoma in the oral cavity: a case report. J Oral Maxillofac Surg. 2007; 65: 1361-1364.
21. Johnson NA, Boyle M, Bashashati A, et al. Diffuse large B-cell lymphoma: reduced CD20 expression is associated with an inferior survival. Blood. 2009; 113: 3773-3780.
22. Rajkumar SV, Fonseca R, Lacy MQ, et al. Plasmablastic morphology is an independent predictor of poor survival after autologous stem-cell transplantation for multiple myeloma. J Clin Oncol. 1999; 17: 1551-1557.
23. Castillo JJ, Winer ES, Stachurski D, et al. Prognostic factors in chemotherapy-treated patients with HIV-associated plasmablastic lymphoma. Oncologist. 2010; 15: 293-299.
24. National Comprehensive Cancer Network (NCCN). NCCN Guidelines, Version 3.2011: AIDS-Related B-Cell Lymphoma. AIDS-3. Available at: http://www.nccn.org. Accessed October 31, 2011.
25. Liu JJ, Zhang L, Ayala E, et al. Human immunodeficiency virus (HIV)-negative plasmablastic lymphoma: a single institutional experience and literature review. Leuk Res. 2011; 35: 1571-1577.
26. Bibas M, Grisetti S, Alba L, et al. Patient with HIV-associated plasmablastic lymphoma responding to bortezomib alone and in combination with dexamethasone, gemcitabine, oxaliplatin, cytarabine, and pegfilgrastim chemotherapy and lenalidomide alone. J Clin Oncol. 2010; 28: e704-e708.
27. Bose P, Thompson C, Gandhi D, et al. AIDS-related plasmablastic lymphoma with dramatic, early response to bortezomib. Eur J Haematol. 2009; 82: 490-492.
28. Dunleavy K, Pittaluga S, Czuczman MS, et al. Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood. 2009; 113: 6069-6076.